Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood test could tailor leukemia drug dosing

NCT ID NCT06030089

Knowledge-focused Sponsor: Centre Hospitalier Universitaire de Nice Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This pilot study looked at 20 adults with acute myeloid leukemia (AML) who were not healthy enough for strong chemotherapy. They received a standard combination of azacitidine and venetoclax. Researchers measured venetoclax levels in the blood at several time points to see if those levels relate to how well the drug works and how toxic it is. The goal is to gather information that could lead to personalized dosing in the future.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
venetoclax and azacitidine
What this could lead to
If successful, this could help doctors personalize venetoclax dosing for AML patients, potentially improving treatment effectiveness and reducing side effects.
What could go wrong
This is a very small pilot study with only 20 participants, so results may not apply to everyone. It is designed to gather information, not to prove a new treatment works.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

20 people

The number who actually took part.

Started

Feb 2024

Finished

Mar 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria : * Patient with acute myeloid leukemia (AML) not eligible for intensive chemotherapy * Patients aged 18 or over * Patient treated with the combination azacitidine (AZA) + venetoclax (VEN) * Patient having signed the study informed consent form * Patient with social security coverage Exclusion criteria : * Patients receiving treatment inhibiting or inducing Cytochrome CYP3A4 * Presence of an active, uncontrolled infection * Patient participating or having participated in a clinical drug trial in the month prior to inclusion. * Vulnerable persons

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute myeloid leukemia are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute myeloid leukemia

Contacts and locations

Locations

  • CHU de Nice

    Nice, France

  • Hopital la Conception

    Marseille, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.